Teva phase iv unite study shows ajovy® (fremanezumab) reduced migraine attacks and depression symptoms in migraine sufferers with major depressive disorder

Tel aviv, israel--(business wire)--teva pharmaceutical industries ltd. (nyse and tase: teva) announce that data from the unite study presented today at the world congress of neurology in montreal, canada, show that ajovy® (fremanezumab) reduced migraine attacks and depression symptoms in migraine patients with major depressive disorder. ajovy® is currently approved for the preventive treatment of migraine in adults. depression is one of the most prevalent psychiatric co-morbidities in migraine.
TEVA Ratings Summary
TEVA Quant Ranking